Author

Andrew E. Walker

Observed names: A Walker, A. Walker, A.R. Walker

Institution: University of North Carolina at Chapel Hill

Observed institutions: University of North Carolina at Chapel Hill, University of Glasgow

ORCID: 0009-0006-1729-3913

Observed ORCID: 0009-0006-1729-3913

OpenAlex ID: A5111743336

Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer

2002 · A D Purushotham, E McLatchie, et al. · British journal of surgery · 123

Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcome

2009 · M. Sharpe, J. Stone, et al. · Psychological Medicine · 110

The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

2013 · W. Su, A. Walker, et al. · Value in Health · 4

Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER− breast cancer: A retrospective cohort study

2025 · Andrew E. Walker, Xiaohua Gao, et al. · PLoS Medicine · 3

PND23 Economic Evaluation of Natalizumab Versus Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis in Sweden

2012 · S.T. Alexopoulos, B. Deniz, et al. · Value in Health · 1

PND1 A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients With Relapsing-Remitting Multiple Sclerosis

2012 · A.R. Walker, B. Deniz, et al. · Value in Health · 1

Prognostic Significance of CD8 T-cell Spatial Biomarkers in ER+ and ER-Breast Cancer

2025 · Andrew E. Walker, Xiaohua Gao, et al. · medRxiv

POSA68 Cost Minimization Analysis of Fixed-Dose Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Versus Open Triple Therapy for Moderate-to-Very Severe COPD in the United Kingdom

2022 · E de Nigris, U Holmgren, et al. · Value in Health

PCN130 Modeling Approaches in Cost-Effectiveness Analysis (CEA) of First-Line (1L) Immuno-Oncology (IO) Therapies in Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

2020 · T. Kongnakorn, A. Walker, et al. · Value in Health

Cost-Per-Responder of Fixed Combination Calcipotriol + Betamethasone Dipropionate Aerosol Foam Vs Ointment In Patients With Psoriasis Vulgaris In The UK

2017 · A Walker, F Oluwa, et al. · Value in Health

Estimation of time to reach rrms edss health states ≥ 7.0 or Spms for delayed-release Dimethyl Fumarate

2015 · A. Walker, M. Berling, et al. · Value in Health

Works count: 11

Citation count: 242

H-index: 3

I10-index: 2